Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
We want to learn if dasatinib will make triple negative breast cancers smaller. We also hope
that we can learn more about what makes triple negative breast cancers grow. We believe this
information will help us to predict which patients will benefit from taking this drug or
other drugs like it.
This study is a "neoadjuvant study", which means that it is only open to women who have not
had any treatment for their breast cancer. Neoadjuvant studies allow the study doctor to look
at how the cells in your cancer change after taking the study medication. This will help us
to understand whether or not dasatinib is an effective treatment for breast cancer. It will
also help us to learn more about triple negative breast cancer and how to treat it.